Skip to content

Epizyme Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refractory Follicular Lymphoma Patients

7/26/2021

Epizyme informs OSMO that they have launched the EZH2Now Testing Program, an Epizyme initiative in collaboration with Quest Diagnostics, the leading provider of diagnostic information services, to provide free EZH2 mutation testing for patients with relapsed or refractory (R/R) follicular lymphoma (FL). Quest Diagnostics will coordinate directly with your local lab, including Kaiser, to obtain tissue for testing. Follow this link to begin the order process: https://epizymenow.com/hcp/ezh2now-form

Powered By GrowthZone